Puma registered a turnaround in profitability, posting GAAP net income of $5.9 million against a GAAP net loss of$4.5 million in Q2 2024. Expense control was a major factor. Selling, general and administrative (SG&A) costs (GAAP) dropped to $18.0 million, down 28$15.5 million compared to Q2 2024 (GAAP), mainly due to higher costs linked to trials of alisertib, the investigational cancer trea ...